Effects of SGLT2 Inhibitors on Patients with Diabetic Kidney Disease: A Preliminary Study on the Basis of Podocyturia

Overview

Journal J Diabetes

Specialty Endocrinology

Date 2022 Mar 1

PMID 35229458

Authors

Emre Durcan

Serbay Ozkan

Halil Ibrahim Saygi

Mevlut Tamer Dincer

Ozge Polat Korkmaz

Serdar Sahin

Cebrail Karaca

Cem Sulu

Alev Bakir

Hande Mefkure Ozkaya

Sinan Trabulus

Elif Guzel

Nurhan Seyahi

Mustafa Sait Gonen

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to investigate the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the glomerulus through the evaluation of podocyturia in patients with diabetic kidney disease (DKD).

Methods: The study population was composed of 40 male patients with type 2 diabetes mellitus; 22 of them received SGLT2i (SGLT2i group), and the others who did not were the control. The DKD-related parameters of patients were monitored before SGLT2i initiation, and then in the third and sixth month of the follow-up period. Patients' demographic, clinical, laboratory, and follow-up data were obtained from medical charts. Microalbuminuria was measured in 24-h urine. The number of podocytes in the urine was determined by immunocytochemical staining of two different markers, namely podocalyxin (podx) and synaptopodin (synpo). Concentrations of urine stromal cell-derived factor 1a and vascular endothelial growth factor cytokines were quantified with an enzyme-linked immunosorbent assay kit.

Results: At the end of the follow-up period, decreases in glycosylated hemoglobin, glucose, systolic and diastolic blood pressure, uric acid level, and microalbuminuria, and improvement in body mass index level and weight loss were significant for the SGLT2i group. On the other hand, there was no significant difference in terms of these parameters in the control group. The excretion of synaptopodin-positive (synpo ) and podocalyxin-positive (podx ) cells was significantly reduced at the end of the follow-up period for the SGLT2i group, while there was no significant change for the control.

Conclusions: At the end of the follow-up period, male patients receiving SGLT2i had better DKD-related parameters and podocyturia levels compared to baseline and the control group. Our data support the notion that SGLT2i might have structural benefits for glomerular health.

Citing Articles

Canagliflozin Attenuates Podocyte Inflammatory Injury through Suppressing the TXNIP/NLRP3 Signaling Pathway in Diabetic Kidney Disease Mice.

Li S, Wang J, Chen Y, Cheng Y, Wang Y, Xu N Inflammation. 2025; .

PMID: 40067577 DOI: 10.1007/s10753-025-02258-9.

Podocyturia an emerging biomarker for kidney injury.

Hanna C, Etry H, Ibrahim M, Khalife L, Bahous S, Faour W BMC Nephrol. 2025; 26(1):118.

PMID: 40045253 PMC: 11884025. DOI: 10.1186/s12882-025-04039-w.

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near.

Portalatin G, Hong-McAtee I, Burgner A, Gould E, Hunley T Front Pediatr. 2025; 13:1521425.

PMID: 39950157 PMC: 11821607. DOI: 10.3389/fped.2025.1521425.

Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes.

Li X, Li Q, Jiang X, Song S, Zou W, Yang Q Cell Commun Signal. 2024; 22(1):534.

PMID: 39511548 PMC: 11542362. DOI: 10.1186/s12964-024-01914-1.

A non-linear association between low-density lipoprotein cholesterol and the risk of diabetic kidney disease in patients with type 2 diabetes in China.

Xiang X, Chen G, Ma Y, Wang H Prev Med Rep. 2024; 45:102840.

PMID: 39175593 PMC: 11339054. DOI: 10.1016/j.pmedr.2024.102840.

References

Vestri S, Okamoto M, de Freitas H, Aparecida Dos Santos R, Nunes M, Morimatsu M . Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001; 182(2):105-12. DOI: 10.1007/s00232-001-0036-y. View

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C . In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005; 166(5):1309-20. PMC: 1606387. DOI: 10.1016/S0002-9440(10)62350-4. View

Sato Y, Wharram B, Lee S, Wickman L, Goyal M, Venkatareddy M . Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009; 20(5):1041-52. PMC: 2678045. DOI: 10.1681/ASN.2007121328. View

Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J . Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017; 21(2):1-218. PMC: 5292646. DOI: 10.3310/hta21020. View

Abdul-Ghani M, Norton L, DeFronzo R . Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. DOI: 10.1210/er.2010-0029. View

Haraldsson B, Nystrom J, Deen W . Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008; 88(2):451-87. DOI: 10.1152/physrev.00055.2006. View

Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X . Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020; 10(1):14790. PMC: 7478957. DOI: 10.1038/s41598-020-71908-9. View

Zhang L, Feng Y, List J, Kasichayanula S, Pfister M . Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12(6):510-6. DOI: 10.1111/j.1463-1326.2010.01216.x. View

Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou M . The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019; 37(7):1334-1343. DOI: 10.1097/HJH.0000000000002050. View

10.

Nagata M . Podocyte injury and its consequences. Kidney Int. 2016; 89(6):1221-30. DOI: 10.1016/j.kint.2016.01.012. View

11.

Wang X, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L . SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE. J Biol Chem. 2017; 292(13):5335-5348. PMC: 5392679. DOI: 10.1074/jbc.M117.779520. View

12.

Neal B, Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Ways K . Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2014; 38(3):403-11. DOI: 10.2337/dc14-1237. View

13.

Kostovska I, Tosheska Trajkovska K, Cekovska S, Topuzovska S, Kavrakova J, Spasovski G . Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Rom J Intern Med. 2020; 58(4):233-241. DOI: 10.2478/rjim-2020-0023. View

14.

Kopp J, Anders H, Susztak K, Podesta M, Remuzzi G, Hildebrandt F . Podocytopathies. Nat Rev Dis Primers. 2020; 6(1):68. PMC: 8162925. DOI: 10.1038/s41572-020-0196-7. View

15.

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C . SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018; 3(15). PMC: 6129124. DOI: 10.1172/jci.insight.98720. View

16.

Sanchez-Nino M, Perez-Gomez M, Valino-Rivas L, Torra R, Ortiz A . Podocyturia: why it may have added value in rare diseases. Clin Kidney J. 2019; 12(1):49-52. PMC: 6407136. DOI: 10.1093/ckj/sfy081. View

17.

Pfister M, Whaley J, Zhang L, List J . Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011; 89(4):621-5. DOI: 10.1038/clpt.2011.16. View

18.

Yu D, Petermann A, Kunter U, Rong S, Shankland S, Floege J . Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005; 16(6):1733-41. DOI: 10.1681/ASN.2005020159. View

19.

Vallon V, Richter K, Blantz R, Thomson S, Osswald H . Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999; 10(12):2569-76. DOI: 10.1681/ASN.V10122569. View

20.

Cherney D, Lund S, Perkins B, Groop P, Cooper M, Kaspers S . The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016; 59(9):1860-70. DOI: 10.1007/s00125-016-4008-2. View